Brief: Infinity Pharmaceuticals Presents New Mario-1 Phase 1/1B Clinical Data At SITC
09/11/2020 14:30
Nov 9 (Reuters) - Infinity Pharmaceuticals Inc INFI.O :
* INFINITY PHARMACEUTICALS - PRESENTS NEW MARIO-1 PHASE 1/1B
CLINICAL DATA AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 35TH
ANNIVERSARY ANNUAL MEETING
* INFINITY PHARMACEUTICALS INC - DATA FROM MELANOMA AND
SCCHN
COHORTS DEMONSTRATE EGANELISIB WAS WELL TOLERATED IN COMBINATION
WITH OPDIVO
Source text for Eikon: ID:nBwc7JrnYa
Further company coverage: INFI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Infinity Pharmaceuticals
See all newsBrief: Infinity Pharmaceuticals Filed Voluntary Petition For Relief Under Provisions Of Chapter 11
Brief: Infinity Pharmaceuticals Inc Received Determination Letter From Nasdaq On September 12
Brief: Infinity Pharma Says On Sept 5, 2023, Co Received Letter From Nasdaq Notifying That Listing Of Common Stock Was Not In Compliance With Nasdaq Listing Rule
Brief: Infinity Pharmaceuticals Approved Plan To Reduce Co's Overall Headcount By 21 Positions
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX